Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Melissa BadamoMyeloma | February 27, 2024
The target action date for the FDA’s decision is August 22, 2024.
Read More
Melissa BadamoMyeloma | February 27, 2024
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
Melissa BadamoMyeloma | February 22, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Blood Cancers Today Staff WritersMyeloma | February 21, 2024
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Advertisement
Patrick DalyMyeloma | February 27, 2024
Belamaf, bortezomib, and dexamethasone improved survival versus daratumumab bortezomib, and dexamethasone in myeloma.
Melissa BadamoPrint | February 29, 2024
Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression.
Leah LawrenceMyeloma | February 8, 2024
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Patrick DalyMyeloma | February 7, 2024
The Marketing Authorization Application for linvoseltamab has been submitted and is under review by the EMA.
Melissa BadamoMyeloma | February 12, 2024
A higher percentage of patients receiving daratumumab achieved negative MRD compared with patients who did not.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Patrick DalyMyeloma | January 30, 2024
The CHMP of the European Medicines Agency gave a positive recommendation for the Marketing Authorization approval of ide-cel.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Melissa BadamoMyeloma | February 2, 2024
The study aimed to describe the myeloma-defining events and clinical presentations leading to multiple myeloma diagnosis.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Melissa BadamoMyeloma | February 2, 2024
The study also identified 12 distinct subtypes of myeloma, expanding on previous classifications.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Dwight Macero, PA-C, MSMyeloma | January 8, 2024
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Blood Cancer TalksBlood Cancer Talks | January 10, 2024
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Advertisement
Advertisement
Editorial Board